Pfizer Ends Study On Potential Lung Cancer Drug
Source: Seattle Post-Intelligencer
Thursday 11th March, 2010
THE ASSOCIATED PRESS NEW YORK -- Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectivene... ...
Read the full story at
Seattle Post-Intelligencer
Email this story to a friend
Have your say on this story
